CNS Therapeutics

Global CNS Therapeutics Market to Reach US$199.0 Billion by 2030

The global market for CNS Therapeutics estimated at US$130.6 Billion in the year 2024, is expected to reach US$199.0 Billion by 2030, growing at a CAGR of 7.3% over the analysis period 2024-2030. Neurodegenerative Diseases, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$75.9 Billion by the end of the analysis period. Growth in the Mental Health segment is estimated at 7.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$52.4 Billion While China is Forecast to Grow at 11.5% CAGR

The CNS Therapeutics market in the U.S. is estimated at US$52.4 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$19.9 Billion by the year 2030 trailing a CAGR of 11.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.6% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.1% CAGR.

Global CNS Therapeutics Market - Key Trends & Drivers Summarized

Central Nervous System (CNS) therapeutics encompass a broad range of treatments aimed at addressing disorders and diseases of the brain and spinal cord. These include conditions such as Alzheimer`s disease, Parkinson`s disease, epilepsy, depression, and multiple sclerosis. CNS therapeutics comprise pharmaceuticals, biologics, and advanced therapies like gene and cell therapies. The complexity of the CNS and the blood-brain barrier poses significant challenges in developing effective treatments, but advances in neuroscience, molecular biology, and drug delivery systems are leading to innovative therapeutic approaches. Precision medicine and personalized treatments are becoming increasingly important in CNS therapeutics, offering the potential for more targeted and effective interventions.

The market for CNS therapeutics is driven by the high prevalence of neurological and psychiatric disorders, which significantly impact the quality of life and healthcare systems worldwide. An aging population is contributing to the rising incidence of neurodegenerative diseases like Alzheimer`s and Parkinson`s. Additionally, increased awareness and better diagnostic capabilities are leading to earlier detection and treatment of CNS conditions. The pharmaceutical industry is heavily invested in CNS research and development, resulting in a robust pipeline of new drugs and therapies. Regulatory agencies are also prioritizing the approval of innovative treatments for CNS disorders, recognizing the urgent need for effective solutions.

The growth in the CNS therapeutics market is driven by several factors. Firstly, the increasing prevalence of neurological and psychiatric disorders due to aging populations and improved diagnostics is boosting demand for CNS treatments. Secondly, significant advancements in neuroscience research and drug development are leading to new and more effective therapeutic options. Thirdly, the growing emphasis on precision medicine and personalized therapies is enhancing treatment efficacy and patient outcomes. Lastly, supportive regulatory environments and the prioritization of CNS disorder treatments are accelerating the approval and commercialization of new therapies. These factors collectively contribute to the dynamic growth of the CNS therapeutics market.

SCOPE OF STUDY:

The report analyzes the CNS Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Segment (Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, CNS Trauma, Infectious Diseases, CNS Cancer, Other Segments)

Geographic Regions/Countries:
World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 353 Featured) -

• Abbott Laboratories, Inc.
• AbbVie, Inc.
• Acumen Pharmaceuticals, Inc.
• Alexza Pharmaceuticals
• A. Menarini Industrie Farmaceutiche Riunite Srl
• AC Immune SA
• Addex Therapeutics
• Ache Laboratorios Farmaceuticos SA
• 4D pharma plc
• Acadia Pharmaceuticals, Inc.
• AB Science SA
• ABL Bio, Inc.
• AcelRx Pharmaceuticals
• Aarti Drugs Ltd.
• Abion

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.